Grifols SA (GRFS) Upgraded to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of Grifols SA (NASDAQ:GRFS) from a sell rating to a buy rating in a report issued on Wednesday morning. Zacks Investment Research currently has $18.00 target price on the stock.
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Separately, Morgan Stanley reissued a sell rating on shares of Grifols SA in a research note on Monday, June 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Grifols SA has an average rating of Hold and a consensus price target of $20.25.
Grifols SA (NASDAQ:GRFS) opened at 16.03 on Wednesday. Grifols SA has a 12-month low of $14.07 and a 12-month high of $18.04. The company has a market cap of $21.91 billion, a price-to-earnings ratio of 36.56 and a beta of 0.94. The firm’s 50-day moving average is $16.25 and its 200 day moving average is $16.01.
Institutional investors have recently added to or reduced their stakes in the stock. Bogle Investment Management L P DE boosted its position in shares of Grifols SA by 220.9% in the first quarter. Bogle Investment Management L P DE now owns 536,548 shares of the company’s stock worth $8,300,000 after buying an additional 369,352 shares during the period. OLD Mission Capital LLC boosted its position in shares of Grifols SA by 1,452.7% in the first quarter. OLD Mission Capital LLC now owns 98,409 shares of the company’s stock worth $1,522,000 after buying an additional 92,071 shares during the period. Geode Capital Management LLC boosted its position in shares of Grifols SA by 7.0% in the first quarter. Geode Capital Management LLC now owns 64,527 shares of the company’s stock worth $998,000 after buying an additional 4,240 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Grifols SA by 147.2% in the first quarter. Goldman Sachs Group Inc. now owns 3,024,316 shares of the company’s stock worth $46,786,000 after buying an additional 1,800,775 shares during the period. Finally, Riverhead Capital Management LLC boosted its position in shares of Grifols SA by 96.0% in the first quarter. Riverhead Capital Management LLC now owns 39,396 shares of the company’s stock worth $610,000 after buying an additional 19,296 shares during the period. Institutional investors and hedge funds own 20.18% of the company’s stock.
Receive News & Stock Ratings for Grifols SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA and related stocks with our FREE daily email newsletter.